COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
ActiTrexx GmbH develops ATreg: IV‑administered activated regulatory T cells via a proprietary activation process for prophylaxis and treatment of graft‑versus‑host disease and autoimmune conditions.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
